What You Should Know:
- Eko, a cardiopulmonary digital health company launches its next-generation Eko DUO, an FDA-cleared cardiac assessment tool that functions as an electrocardiogram (ECG) and digital stethoscope to detect early signs of heart disease and facilitate timely care and personalized disease management.
- DUO is a pocket-sized cardiac examination system for clinicians used to detect early signs of heart disease and facilitate timely care for patients in and out of the clinic.
Read More
Eko Devices
Eko’s AI Algorithm Validated as a Clinical Tool for Detecting Heart Murmurs
What You Should Know:
- Eko, a cardiopulmonary digital health company, today announced the peer-reviewed publication of a clinical study that found that the Eko artificial intelligence (AI) algorithm for detecting heart murmurs is accurate and reliable, with comparable performance to that of an expert cardiologist.
- The findings suggest utility of the FDA-cleared Eko AI algorithm as a front line clinical tool to aid clinicians in screening for cardiac murmurs
Read More
Eko Lands $65M to Expand AI-Powered Telehealth Platform for Virtual Pulmonary and Cardiac Exam
What You Should Know:
- Cardiopulmonary digital health company Eko raises $65M
in Series C funding to close the gap between virtual and in-person heart and
lung care.
- The latest round of funding will enable Eko to expand
in-clinic use of its platform of telehealth and AI algorithms for disease
screening and to launch a monitoring program for cardiopulmonary patients at
home.
Eko, a
cardiopulmonary digital
health company,
today announced $65 million in Series C funding led by
Read More
3M and Eko Launches 3M Littmann® CORE Digital Stethoscope for Clinicians
What You Should Know:
- 3M and Eko team up to launch 3M Littmann® CORE Digital
Stethoscope to deliver a game-changing tool for clinicians as they assess,
diagnose, and monitor their patients.
- The new 3M Littmann CORE Digital Stethoscope offers
clinicians access to both analog and digital auscultation options and connects
to Eko’s software and AI algorithms* to help clinicians better interpret sounds
and detect heart murmurs.
3M™ Littmann® Stethoscopes and Eko, today announced the
Read More
FDA Grants Eko Emergency Use Authorization for Low Ejection Fraction AI
What You Should Know:
- The FDA granted Emergency Use Authorization to Eko for an ECG-based algorithm that screens for low ejection fraction, as part of an assessment of cardiac complications and co-morbidities associated with COVID-19.
- This ECG-based deep learning algorithm, developed on a large clinical dataset in collaboration with the Mayo Clinic, can help efficiently identify signs of possible heart failure in patients.
Eko, a digital health
company building
Read More
Eko Unveils Redesigned Smart Stethoscope and Stethoscope Attachment
- Eko unveils the second generation of CORE products, which includes a smart stethoscope and a stethoscope attachment designed to make any existing stethoscope smarter.- The technological advancements of the CORE include active noise cancellation, sleeker design, and powerful software to allow medical professionals to more effectively screen for heart disease.- The CORE Digital Attachment ($199) and the fully assembled CORE Digital Stethoscope ($249) are available for pre-order now to healthcare
Read More
Heart Failure is Detectable at Point of Care Using ECG-Enabled Stethoscope, Mayo Clinic and Eko Finds
- Eko and Mayo Clinic announced they have proven that heart failure is detectable during routine physical exams, further validating the Eko DUO digital stethoscopes as a heart failure screening tool. - Today’s news marks the first time that a point of care device with a single lead ECG combined with an AI algorithm identified low ejection fraction in patients.- The results of these findings, which are comparable to research published earlier this year in NatureMedicine, were presented over the
Read More
Eko Raises $20M to Expand Machine Learning Platform for Cardiac Monitoring/Analysis
- AI-driven digital health startup Eko raises $20M led by ARTIS Ventures with participation from 3M and Mayo Clinic.
- Funding will be used to accelerate research and development (R&D) and commercialization of Eko’s machine learning platform for cardiac screening/analysis.
- Eko’s cardiac monitor combines digital stethoscope and ECG technology both for in-clinic and at-home monitoring, which enables patients to seamlessly and consistently send cardiac data to their
Read More
Backed by Mayo Clinic Study, Eko Launches Cardiac Remote Monitoring App, Eko Home
Currently being used in a study by Mayo Clinic, cardiac monitoring app Eko Home enhances outpatient cardiac data collection and demonstrates real world efficacyEko, a Silicon Valley-based digital health company applying machine learning in the fight against heart disease, today announced its cardiac remote monitoring app, Eko Home. The app is a first-of-its-kind service that enables precise remote monitoring of cardiac function using ECG and heart sounds. Eko Home can be used to create drug-data
Read More
Eko Unveils Investigational Aortic Stenosis (AS) Detection Algorithm
Eko, a Berkeley-based digital health company applying artificial intelligence and machine learning in the fight against heart disease unveiled an investigational Aortic Stenosis (AS) detection algorithm at the American Society of Echocardiography (ASE) 2019 Scientific Sessions aimed to assist healthcare providers in the early detection of clinically significant AS. The algorithm represents a major step forward toward Eko’s mission to empower healthcare providers with tools to more accurately
Read More
